Nvidia’s Q3 FY27: The Reassurance Before the Storm
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
Odds the $NVDA 10-Q never gets filed? Odds that, if it is filed, it misses the filing date at least twice? Serious questions.
Can’t let these weirdos win. Use $GOOG Gemini Neon
Can’t let these weirdos win. Use $GOOG Gemini Neo
@MarkGroskyEsq @grok can the remaining ~$1.3B be reversed or no because it went through depreciation and amortization for $ZIM
Nvidia faced China workaround enforcement concerns as technology fell 6%; energy rose 4.5%, while the company raised eFY28 revenue growth…
MiniMed's 15.8% Q1 organic growth and 20% U.S. pump-volume increase support a product-cycle recovery as split-off selling fades.
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and guided $130 billion, while Jensen Huang’s resignation left Colette Kress as…
Pfizer’s Q3 revenue reached $16.58 billion, launched and acquired products grew 32%, and FY26 guidance rose to $62 billion to $64 billion.
NVIDIA’s fiscal third-quarter 2027 results are its first earnings report since Jensen Huang’s resignation as CEO.
UFP Industries trades near its 2022 price despite EPS falling 62%; a $95–$105 valuation assumes $6.30 normal-year EPS, with freight and…
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and raised its fiscal 2028 growth outlook to 75% as interim CEO Colette Kress…
Century Aluminum (CENX) could benefit from U.S. tariffs, Midwest aluminum premiums and constrained global supply, with the stock trading…
Figma grew Q3 revenue 43% to $391.4 million, raised FY2026 guidance to nearly $1.5 billion and guided Q4 above consensus despite the stock…
Nvidia raised its fiscal 2028 growth outlook, but shares reversed as investors focused on uncertainty beyond January 2028.
BNTC · long Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.
Microsoft, Amazon, Oracle, Meta and Alphabet face another two years of record AI data-center investment amid $3 trillion in commitments,…
Intuit trades at historically low multiples as DIY tax pricing pressure and customer losses test its growth, while assisted tax, Money and…
Meta’s Muse and rival AI agents are gaining consumer traction, while Apple and Google lack comparable public products and face pressure on…
Kratos raised 2026 guidance to $1.75–$1.81 billion revenue and $173–$176 million adjusted EBITDA after an equity raise, with drones,…
Intel’s Panther Lake puts 18A PowerVia backside power and RibbonFET GAA transistors into commercial silicon, with logic density similar to…
Honeywell Aerospace, newly spun off as HONA, fell 41% from post-listing highs after Q2 2026 as supply-chain bottlenecks delayed revenue…
VersaBank uses cash holdbacks and put-backs to buy point-of-sale loan cash flows, with C$7 billion in assets and AI-enabled real-time…
GitLab's Q2 FY2027 beat and raised guidance reflect large deals, paid consumption growth and AI demand, while valuation rests on revenue…
FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.